Form 4: Protara Therapeutics Exec Sells Shares

Protara Therapeutics CEO and President Jesse Shefferman reported transactions involving company stock, including the acquisition of shares at $1.91 and the sale of shares at an average of $4.09.

Summary

• Jesse Shefferman, CEO and President of Protara Therapeutics, Inc. (TARA), reported several transactions on June 29 and June 30, 2026.
• On June 29, 2026, Shefferman acquired 215,687 shares of common stock at a price of $1.91 per share, increasing his beneficial ownership to 937,519 shares.
• On the same day, he disposed of 215,687 shares of common stock at a weighted average price of $4.09 per share, with individual sale prices ranging from $4.03 to $4.14.
• Following these sales, his beneficial ownership of common stock decreased to 721,832 shares.
• Additional disposals of common stock occurred on June 30, 2026, totaling 27,000 shares, reducing his direct ownership further.
• Shefferman also holds 300,000 shares indirectly through The Samhold Family Trust.
• A stock option to purchase 215,687 shares of common stock at an exercise price of $1.91, with an expiration date of January 18, 2034, was also noted. 25% of these shares vested on January 19, 2025, with the remainder vesting monthly over 36 months, subject to continued service.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While the sale of shares by the CEO could be seen negatively, the acquisition at a lower price and the retention of a significant number of shares balance this out. The explanation for prior filing errors also mitigates potential concern.

Positives

• Acquisition of 215,687 shares at a lower price point ($1.91) suggests potential for future appreciation or a strategic purchase.
• The reporting person retains a significant number of shares (721,832 directly, 300,000 indirectly) indicating continued investment in the company.
• Stock options with a strike price of $1.91, if exercised and the stock price rises above this, represent potential upside for the executive.

Negatives

• Sale of 215,687 shares at a higher price ($4.09 average) could indicate the executive believes the stock is currently overvalued or is diversifying holdings.
• The disposal of shares at a price significantly higher than the acquisition price might suggest a profit-taking strategy.

Risks

• The sale of a substantial number of shares by a key executive could be interpreted negatively by the market, potentially impacting share price.
• The explanation regarding the Samhold Family Trust holdings suggests prior inadvertent inclusions in filings, raising minor concerns about reporting accuracy.
• Vesting of stock options is contingent on continued service, introducing a risk of forfeiture if the executive's employment status changes.

Future Outlook

The filing does not contain explicit forward-looking statements or guidance. However, the vesting schedule of stock options implies continued service and potential future equity value for the executive.

Management Comments

• The reporting person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest, and this report should not be deemed an admission that the Reporting Person or any other person named herein is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
• The reported securities held by the Samhold Family Trust were inadvertently included under the Reporting Person's direct holdings in the prior Form 4 filings filed by the Reporting Person on January 21, 2026, January 22, 2026 and January 27, 2026.

Industry Context

StockSavvy.ai notes that Form 4 filings by executives are common and provide transparency into insider transactions. The acquisition at a lower price and sale at a higher price is a typical pattern, but the volume of shares sold by a CEO warrants attention from investors monitoring insider sentiment.

Related Party Transactions

• The filing notes that securities held by The Samhold Family Trust were previously reported under the Reporting Person's direct holdings, indicating a past administrative error in reporting related party or indirect holdings.

Stakeholder Impact

• Shareholders: May interpret the CEO's sale of shares as a signal of reduced confidence or profit-taking, potentially influencing short-term stock price. However, the acquisition at a lower price and continued significant holdings may temper negative sentiment.
• Employees: The CEO's continued service and option vesting schedule suggest ongoing commitment, which can be a positive signal.
• Creditors: No direct impact is indicated by this filing.

Next Steps

• Continued monthly vesting of stock options over the next 36 months, subject to continued service.
• Potential future filings of Form 4 by Jesse Shefferman to report further transactions.

Key Dates

Recommendation

The filing details routine insider transactions, including the sale of shares at a profit and the acquisition of shares at a lower price, alongside stock option activity. While the sale of a significant number of shares by the CEO could be a concern, the simultaneous acquisition and the executive's continued substantial beneficial ownership suggest a balanced approach rather than a strong negative signal. Therefore, a 'hold' recommendation is appropriate pending further company-specific developments.

Keywords

Protara Therapeutics, TARA, Form 4, SEC Filing, Insider Trading, Stock Options, Beneficial Ownership, Jesse Shefferman, Shareholder, Executive Compensation